Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor

PurposeThe prognosis of relapsed or refractory pediatric Wilms tumor (WT) is dismal, and new salvage therapies are needed. This study aimed to evaluate the efficacy of the combination of irinotecan and a doxorubicin hydrochloride liposome regimen for relapsed or refractory pediatric WT.Patients and...

Full description

Bibliographic Details
Main Authors: Juan Wang, Lian Zhang, Lanying Guo, Yi Que, Yu Zhang, Feifei Sun, Jia Zhu, Suying Lu, Junting Huang, Liuhong Wu, Ruiqing Cai, Zijun Zhen, Sihui Zeng, Yizhuo Zhang, Xiaofei Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
Wilms tumor
pediatric tumor
salvage regimen
irinotecan
doxorubicin hydrocloride liposome
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.721564/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.721564/full

Similar Items